ArticleJournal of cardiothoracic surgery2026
Surgery versus chemoradiotherapy in patients with stage T1-2N0M0 small cell lung cancer: a retrospective cohort study.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare survival outcomes of surgical resection versus concurrent chemoradiotherapy in patients with stage T1-2N0M0 small cell lung cancer (SCLC). MATERIALS AND
methodsWe extracted stage T1-2N0M0 SCLC from the Surveillance, Epidemiology, and End Results database between 2000 and 2020. Kaplan-Meier analysis and Cox proportional hazards regression were employed to assess cancer-specific survival (CSS) and overall survival (OS).
resultsThe study cohort comprised 190 patients undergoing surgical resection and 371 patients receiving chemoradiotherapy. Median CSS was significantly longer in the surgical group compared to the chemoradiotherapy group (123 months vs. 33 months). Multivariable analysis confirmed surgery as an independent protective factor for CSS, both before (hazard ratio [HR] = 0.51, 95% confidence interval [CI]: 0.38–0.68; P < 0.001) and after (HR = 0.52, 95% CI: 0.37–0.73; P < 0.001) propensity score matching. Similarly, surgery was associated with significantly improved OS in multivariable analysis before (HR = 0.58, 95% CI: 0.46–0.73; P < 0.001) and after (HR = 0.60, 95% CI: 0.45–0.80; P < 0.001) propensity score matching. Cumulative incidence analysis revealed a significantly higher 5-year SCLC-specific mortality rate in the chemoradiotherapy group (57.1% vs. 33.8%, P < 0.001). Conversely, 5-year non-cancer mortality (13.3% vs. 16.4%, P = 0.984), lung comorbidity-related mortality (3.5% vs. 3.2%, P = 0.228), and cardiovascular mortality (3.5% vs. 2.6%, P = 0.713) were comparable between the two groups.
conclusionSurgical resection is associated with significantly superior survival outcomes compared to chemoradiotherapy in patients with stage T1-2N0M0 SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.